Intravenous vitamin C

About this approach

Intravenous vitamin C delivers vitamin C directly into a vein and produces higher blood concentrations than oral intake. Researchers have studied it alone and alongside cancer medicines, including possible effects on symptoms and treatment tolerance. It is not FDA-approved as a cancer treatment, and existing research does not establish it as a replacement for standard care. Any discussion should include the quality of the evidence, screening requirements, interactions, and cost.

Where it fits: Investigational approach in cancer care

Where this treatment is used

NCI summarizes human studies with mixed findings, including small trials and combination treatments. Some report improvements in quality of life or fewer treatment-related symptoms; others have not shown an anticancer effect. When studies are small or lack an adequate comparison group, attributing an outcome to vitamin C is difficult. Evidence for one combination and cancer type cannot be extended to all patients. The clinically useful questions concern meaningful outcomes, such as survival or symptom improvement, and whether a well-designed trial supports the proposed use.

Procedure and practical considerations

Serious harm is possible in people with kidney disease, a tendency to kidney stones, G6PD deficiency, or iron-overload disorders such as hemochromatosis. Reported concerns include kidney injury, breakdown of red blood cells in G6PD deficiency, and fluid overload. Potential interactions with anticancer treatment also require assessment.

Clinics reporting this approach

These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.